- NORTH AMERICA EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Top 5 Cannabis Stocks in 2022
Here's a closer look at some of the top cannabis stocks so far in 2022. Find out which companies made the list.
Click here to read the previous top cannabis stocks year-to-date list.
The start of a new year has brought ongoing volatility to the cannabis sector, and has left the biggest companies in the space facing a serious downturn.
Here the Investing News Network lists the top cannabis stocks year-to-date for the Q1 2022 period.
Data for this top cannabis stocks article was collected on April 20, 2022, and the companies included had to meet a minimum market cap requirement of C$10 million. Cannabis companies listed on the NYSE, NASDAQ, TSX, TSXV and CSE were considered. Read on to learn more about the year's biggest gainers.
1. PharmaDrug (CSE:PHRX,OTCQB:LMLLF)
Year-to-date gain: 50 percent; current market cap: C$15.34 million; current share price: C$0.06
PharmaDrug is a pharmaceutical company with cannabis assets spread out through its business. The company owns a German medical cannabis distributor, which gives it exposure to the growing market in Europe.
So far in 2022, PharmaDrug hasn’t offered investors many updates on its cannabis operations; instead, it has shared advancements on its drug programs through its wholly owned Sairiyo Therapeutics biotech company.
The company is exploring a variety of drug treatments for glaucoma, prostate cancer and oncology.
2. Leviathan Natural Products (CSE:EPIC,OTCQB:LVCNF)
Year-to-date gain: 43.33 percent; current market cap: C$73.53 million; current share price: C$0.86
Leviathan Natural Products is a drug-related company working on the development of alternative health products; it is focused on opportunities in the wellness market.
Among its holdings the company has a variety of cannabis-related businesses, including cannabinoid makers, a hemp marketing agency, a licensed operator in Canada and more.
This year the company has undergone significant changes in its management structure, appointing Tanvi Bhandari as CEO and adjusting its board of directors.
3. Cannabix Technologies (CSE:BLO,OTC Pink:BLOZF)
Year-to-date gain: 16.67 percent; current market cap: C$66.2 million; current share price: C$0.63
Cannabix Technologies is an ancillary technology company with the primary business of promoting its cannabis breathalyzer device. In fact, the company unveiled the 4.0 version of its breathalyzer earlier this year.
“Several components such as the device’s internal sampling chambers, microfluidic sensors and related actuation mechanism have been changed to minimize manufacturing variability and to reduce cost,” the company said.
4. BYND Cannasoft Enterprises (CSE:BYND)
Year-to-date gain: 12.24 percent; current market cap: C$148.63 million; current share price: C$5.50
BYND Cannasoft Enterprises is an ancillary business investment point for the cannabis industry thanks to its optimization software solutions. The company presents an international offering as it is based in Israel.
BYND also now holds a growing license in Israel, and plans to produce 7,500 kilograms of raw cannabis each year.
The new year has brought changes at the firm, as it told investors it recently changed its board of directors. Earlier in the year, BYND confirmed its intention to pursue a NASDAQ listing.
5. Delta 9 Cannabis (TSX:DN,OTCQX:DLTNF)
Year-to-date gain: 3.33 percent; current market cap: C$32.4 million; current share price: C$0.31
Manitoba-based cannabis operator Delta 9 Cannabis oversees a lineup of brands available in the domestic market, alongside over 30 stores in the nation. At the end of March, the firm reported record revenue of C$62.3 million for its whole 2021 year, a 20 percent increase from the previous period.
“We remain focused this year to produce growth and improved results as we continue to expand our retail store network, to focus our efforts on sales of our turn key Grow Pods in international markets, and to continue to grow the Company’s cannabis wholesale division,” John Arbuthnot, CEO of Delta 9, told shareholders.
Investor takeaway
The start of 2022 hasn’t brought together a reignition of the green rush for cannabis stocks, with experts pointing to a shift in the way these companies are evaluated.
Despite some stock gains, disappointment in the performance of the overall cannabis market has set in, especially as slow progress on US policy reform tests the patience of market participants.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
- Invest in Cannabis: TSX Cannabis Stocks | INN ›
- CSE Marijuana Stocks | INN ›
- Cannabis Investment: Canadian Cannabis Stocks | INN ›
- US Cannabis Stocks | INN ›
- Cannabis Weekly Round-Up: Cresco and Columbia Care Share Q1 Financials | INN ›
- Are Tobacco and Alcohol Firms Still Interested in Cannabis? | INN ›
- Cannabis Weekly Round-Up: Canopy's Fiscal Year Net Loss Reaches C$320 Million ›
- Can Canadian Cannabis Operators Turn it Around? ›
- Cannabis Waste Extends, How Should Investors Act? ›
- Cannabis Waste Hits Record in Canada, How Should Investors Act? ›
- Cannabis Weekly Round-Up: Earnings Season Continues with Trulieve, TerrAscend ›
- Cannabis Weekly Round-Up: SNDL to Buy Valens ›
- Cannabis Weekly Round-Up: Mike Tyson’s Cannabis Coming to Canada ›
- Cannabis Weekly Round-Up: Democrats Urge Biden for Cannabis Reform ›
- Cannabis Weekly Round-Up: Canopy Growth Updates US Strategy ›
The Beginner’s Guide to Investing in Biotech
Ready to invest in biotech? Our beginner's guide makes it simple to get started.
Download your investing guide today.
Learn About Exciting Investing Opportunities in the Biotech Sector
Your Newsletter Preferences
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.
Bryan is a Senior Editor with INN. After graduating from the Langara journalism program he did some freelance reporting with community newspapers in British Columbia. He initially wrote about the life science space for INN and now spends his time covering the marijuana market, from Canadian LPs to US-based companies, and the impact of this sector on investors.
Learn about our editorial policies.